Welcome to The Canadian Pharmacogenomics Network for Drug Safety (CPNDS)

Adverse drug reactions (also known as ADRs or side effects) are a serious public health problem. Pharmacogenomics is the study of the role of genetics in drug response. Biomarkers of drug response can help predict who is at risk of having an ADR and allow patients and clinicians to make more informed decisions about drug treatment options. This is often referred to as personalized medicine.

CPNDS is helping to solve drug safety problems by developing genetic tests that predict which patients are at risk of serious ADRs. The work of CPNDS is to find drug safety solutions, not just find the genetic basis of ADRs. The research of CPNDS entails collecting patient DNA samples, conducting genetic analyses and comparing the gene profiles of patients who experienced an ADR to those who were on the same medication but did not experience an ADR. Results from these investigations can help develop new treatment approaches for future patients.

CPNDS is a multi-disciplinary team consisting of clinicians, researchers, core support staff and trainees. CPNDS researchers are based at academic health centres across Canada, with 13 paediatric sites and 13 adult sites, all coordinated through the national research hub located at the University of British Columbia in Vancouver, British Columbia. Many international collaborations also exist and are highlighted on this webpage. CPNDS is funded by provincial and federal grants.

See the original post here:
Canadian Pharmacogenomics Network for Drug Safety